RT Journal Article
SR Electronic
T1 The sensitivity of respiratory tract specimens for the detection of SARS-CoV-2: A protocol for a living systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20144543
DO 10.1101/2020.07.02.20144543
A1 Adam J. Moore
A1 Maura I. Nakahata
A1 Chaney C. Kalinich
A1 Kate Nyhan
A1 Daniel J. Bromberg
A1 Xiaoting Shi
A1 Albert I. Ko
A1 Nathan D. Grubaugh
A1 Arnau Casanovas-Massana
A1 Anne L. Wyllie
YR 2020
UL http://medrxiv.org/content/early/2020/07/05/2020.07.02.20144543.abstract
AB Background Highly sensitive, non-invasive, and easily accessible diagnostics for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are essential for the control of the Coronavirus Disease 2019 (COVID-19) pandemic. There is a clear need to establish a gold standard diagnostic for SARS-CoV-2 infection in humans using respiratory tract specimens.Methods Searches will be conducted in the bibliographic databases Medline, Embase, bioRxiv, medRxiv, F1000, ChemRxiv, PeerJ Preprints, Preprints.org, Beilstein Archive, and Research Square. Relevant government documents and grey literature will be sought on the FDA’s Emergency Use Authorizations website, the ECDC’s website, and the website of the Foundation for Innovative New Diagnostics. Finally, papers categorized as diagnosis papers by the EPPI Centre’s COVID-19 living systematic map will be added to our screening process; those papers are tagged with the diagnosis topic based on human review, rather than database searches, and thus this set of papers might include ones that have not been captured by our search strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDJB has received funding from the National Institutes of Health (T32 MH20031). X.S. received a scholarship from China Scholarship Council. AC-M and AIK have received funding through research agreements with Regeneron. ALW has received research funding through grants from Pfizer and the National Basketball Association to Yale and has received consulting fees for participation in advisory boards for Pfizer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review that did not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol for a systematic review and there is no original data available at the time of this submission.